Patents Assigned to Serina Therapeutics, Inc.
-
Publication number: 20240108750Abstract: POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.Type: ApplicationFiled: November 7, 2023Publication date: April 4, 2024Applicant: Serina Therapeutics, Inc.Inventors: J Milton Harris, Michael Bentley, Tacey Viegas, Randall Moreadith, Robert J Sharpe, Kunsang Yoon, Zhihao Fang, Rebecca Weimer
-
Patent number: 11944618Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent the agent linked to the polymer via a linking group containing a cleavable moiety.Type: GrantFiled: April 11, 2022Date of Patent: April 2, 2024Assignee: Serina Therapeutics, Inc.Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
-
Patent number: 11925689Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.Type: GrantFiled: January 4, 2022Date of Patent: March 12, 2024Assignee: Serina Therapeutics, Inc.Inventors: J Milton Harris, Kunsang Yoon, Michael David Bentley, Zhihao Fang, Tacey Viegas
-
Publication number: 20240016798Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.Type: ApplicationFiled: September 19, 2023Publication date: January 18, 2024Applicant: Serina Therapeutics, Inc.Inventors: Michael Bentley, Zhihao Fang, Rebecca Weimer, Tacey Viegas, Randall Moreadith
-
Patent number: 11766432Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.Type: GrantFiled: July 27, 2019Date of Patent: September 26, 2023Assignee: Serina Therapeutics, Inc.Inventors: Michael Bentley, Zhihao Fang, Rebecca Weimer, Tacey Viegas, Randall Moreadith
-
Publication number: 20230009076Abstract: The present disclosure provides for polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer. Methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions comprising a POZ conjugate are also provided.Type: ApplicationFiled: June 28, 2020Publication date: January 12, 2023Applicant: SERINA THERAPEUTICS, INC.Inventors: J Milton HARRIS, Michael D BENTLEY, Tacey X VIEGAS, Randall W MOREADITH, Zhihao FANG, Kunsang YOON, Rebecca WEIMER
-
Publication number: 20220354841Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.Type: ApplicationFiled: April 11, 2022Publication date: November 10, 2022Applicant: Serina Therapeutics, Inc.Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
-
Publication number: 20220249695Abstract: POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.Type: ApplicationFiled: February 4, 2022Publication date: August 11, 2022Applicant: Serina Therapeutics, Inc.Inventors: J Milton HARRIS, Michael Bentley, Tacey Viegas, Randall Moreadith, Robert J. Sharpe, Kunsang Yoon, Zhihao Fang, Rebecca Weimer
-
Publication number: 20220193243Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.Type: ApplicationFiled: January 4, 2022Publication date: June 23, 2022Applicant: Serina Therapeutics, Inc.Inventors: J Milton Harris, Kunsang Yoon, Michael David Bentley, Zhihao Fang, Tacey Viegas
-
Patent number: 11298350Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.Type: GrantFiled: September 30, 2019Date of Patent: April 12, 2022Assignee: Serina Therapeutics, Inc.Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
-
Patent number: 11224595Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.Type: GrantFiled: June 10, 2019Date of Patent: January 18, 2022Assignee: Serina Therapeutics, Inc.Inventors: Randall Moreadith, Michael Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
-
Patent number: 11213588Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.Type: GrantFiled: December 28, 2018Date of Patent: January 4, 2022Assignee: Serina Therapeutics, Inc.Inventors: J Milton Harris, Kunsang Yoon, Michael David Bentley, Zhihao Fang, Tacey Viegas
-
Patent number: 11065340Abstract: In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.Type: GrantFiled: September 10, 2018Date of Patent: July 20, 2021Assignee: Serina Therapeutics, Inc.Inventors: Randall W. Moreadith, Michael D. Bentley, Zhihao Fang, Tacey Viegas
-
Patent number: 10864276Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.Type: GrantFiled: September 27, 2018Date of Patent: December 15, 2020Assignee: Serina Therapeutics, Inc.Inventors: J Milton Harris, Kunsang Yoon, Michael David Bentley, Zhihao Fang, Tacey Viegas, Francesco Maria Veronese, Anna Mero
-
Patent number: 10314837Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.Type: GrantFiled: June 29, 2016Date of Patent: June 11, 2019Assignee: Serina Therapeutics, Inc.Inventors: Randall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
-
Patent number: 10166294Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.Type: GrantFiled: July 8, 2016Date of Patent: January 1, 2019Assignee: Serina Therapeutics, Inc.Inventors: J Milton Harris, Kunsang Yoon, Michael David Bentley, Zhihao Fang, Tacey Viegas
-
Patent number: 10086084Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.Type: GrantFiled: March 8, 2017Date of Patent: October 2, 2018Assignee: Serina Therapeutics, Inc.Inventors: J Milton Harris, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese, Tacey Viegas
-
Patent number: 10071168Abstract: In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.Type: GrantFiled: July 31, 2015Date of Patent: September 11, 2018Assignee: Serina Therapeutics, Inc.Inventors: Randall W Moreadith, Michael D Bentley, Zhihao Fang, Tacey Viegas
-
Patent number: 9284411Abstract: The present disclosure provides novel functional polyoxazoline derivatives prepared by terminating polyoxazoline polymerization with inert chemical groups. In addition, the present disclosure demonstrates the synthesis of novel electrophilic initiators with protected functional groups capable of initiating oxazoline polymerization and capable of surviving the conditions of polymerization. These initiators are used to synthesize the above inert-terminal polyoxazoline derivatives as well as other polyoxazolines with active terminal groups. Furthermore, the present disclosure provides for polyoxazoline-lipid conjugates and liposomal compositions prepared using such polyoxazoline-lipid conjugates. Methods of using the foregoing to prepare conjugates with target molecules are also disclosed.Type: GrantFiled: November 10, 2014Date of Patent: March 15, 2016Assignee: Serina Therapeutics, Inc.Inventors: Michael D Bentley, J Milton Harris, Kunsang Yoon, Michael Reif, Rainer Jordan
-
Patent number: 9169354Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.Type: GrantFiled: February 6, 2012Date of Patent: October 27, 2015Assignee: Serina Therapeutics, Inc.Inventors: Kunsang Yoon, J. Milton Harris, Michael David Bentley